報價延遲最少15分鐘:2026/03/02 22:37 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
258.81 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
6.84/6.52
|
|
企業價值
8.00B
|
| 資產負債 |
|
每股賬面淨值
41.72
|
| 現金流量 |
|
現金流量率
0.02
|
| 損益表 |
|
收益
389.13M
|
|
每股收益
0.30
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company usesits patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates asone operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan. |
